Global Liquid Biopsy Market Size and Forecast (2024-2033)
The global liquid biopsy market is poised for significant growth, projected to reach approximately US$ 15.46 billion by 2033, expanding from US$ 4.29 billion in 2024 at a robust CAGR of 15.30% from 2025 to 2033. This surge is driven by the increasing demand for non-invasive cancer diagnostics, rapid advancements in biomarker discovery, and the growing adoption of personalized medicine.
Download Sample: https://www.renub.com/request-sample-page.php?gturl=liquid-biopsy-market-p.php
Global Liquid Biopsy Market Outlook
A liquid biopsy is a non-invasive diagnostic technique that analyzes biological fluids such as blood to detect cancer and other diseases. Unlike traditional tissue biopsies, which require surgical extraction of tissue samples, liquid biopsies use circulating biomarkers such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes found in the bloodstream.
Key Market Insights
| Report Features | Details |
|---|---|
| Base Year | 2024 |
| Forecast Period | 2025 – 2033 |
| Historical Period | 2020 – 2024 |
| Market Size (2024) | US$ 4.29 Billion |
| Market Forecast (2033) | US$ 15.46 Billion |
| Market Growth Rate (2025-2033) | 15.30% |
Advantages and Applications of Liquid Biopsy
Liquid biopsies are widely employed for early cancer detection, monitoring disease progression, and assessing treatment response. The key advantages of liquid biopsy include:
- Minimally Invasive: Eliminates the need for surgical biopsies, reducing patient discomfort.
- Faster Results: Real-time analysis allows for quicker medical decisions.
- Personalized Treatment Monitoring: Helps track minimal residual disease (MRD) and detect cancer recurrence early.
- Expanding Applications: Beyond oncology, liquid biopsies are now used in prenatal testing, organ transplant monitoring, and genetic disorder detection.
Growth Drivers in the Global Liquid Biopsy Market
1. Increasing Incidence of Cancer and Chronic Diseases
The rising global cancer burden is a primary driver of the liquid biopsy market. In 2024, the U.S. alone is expected to witness 2,001,140 new cancer cases and 611,720 deaths. Liquid biopsies provide an efficient, accurate, and non-invasive means to detect and monitor cancers such as lung, breast, and colorectal cancers, fueling demand.
2. Advancements in Biomarker Technology
Recent advancements in Next-Generation Sequencing (NGS) and molecular diagnostics have enhanced the sensitivity and specificity of liquid biopsies. Innovations in ctDNA analysis, exosome profiling, and digital PCR are improving early disease detection and real-time treatment tracking.
- August 2024: Hitachi High-Tech Corporation and Gencurix, Inc. announced a strategic partnership to advance cancer molecular diagnostics.
3. Shift Towards Non-Invasive Diagnostic Techniques
Patient preference for non-invasive diagnostic methods is a significant factor in market expansion. Liquid biopsies provide minimal recovery time and can be repeated frequently, making them an attractive option for patients with advanced-stage cancer. The increasing use of liquid biopsy in home and outpatient settings further bolsters adoption.
Regional Market Insights
1. United States
The U.S. dominates the global liquid biopsy market, owing to high cancer incidence, a strong biotechnology sector, and FDA approvals for liquid biopsy technologies.
- February 2024: Myriad Genetics acquired select assets from Intermountain Health, strengthening its liquid biopsy portfolio.
2. Germany
Germany leads Europe’s liquid biopsy market, driven by high R&D investment, regulatory support, and strong biotechnology infrastructure.
- September 2024: PreAnalytiX GmbH launched the PAXgene Urine Liquid Biopsy Set, enabling cfDNA analysis from urine samples.
3. China
China is experiencing rapid market growth due to high cancer prevalence and government initiatives to enhance diagnostic access.
- August 2023: China’s National Medical Products Administration approved sunvozertinib for non-small cell lung cancer treatment.
4. Brazil
Brazil leads the Latin American liquid biopsy market due to increasing healthcare investments and cancer awareness initiatives.
Competitive Landscape
The liquid biopsy market features key players driving innovation and market expansion.
Key Companies and Developments
1. F. Hoffmann-La Roche Ltd.
- October 2020: Received FDA approval for its NSCLC liquid biopsy companion diagnostic.
- June 2022: Partnered with the Lung Cancer Research Foundation (LCRF) to enhance lung cancer screening.
2. Guardant Health
- January 2023: Received FDA approval for Guardant360 CDx, a liquid biopsy assay for breast cancer.
- May 2021: Launched the Guardant360 CDx test, the first FDA-approved liquid biopsy for NSCLC.
3. Thermo Fisher Scientific Inc.
- August 2023: Launched the first DNA/RNA-based MRD test for myeloid cancers.
- September 2021: Partnered with AstraZeneca to develop NGS-based companion diagnostics.
4. Bio-Rad Laboratories
- Pioneered droplet digital PCR (ddPCR) technology for detecting Circulating Tumor Cells (CTCs) and cfDNA.
5. Illumina, Inc.
- November 2023: Launched TruSight Oncology 500 ctDNA v2, a next-generation liquid biopsy assay.
- June 2021: Partnered with Bristol Myers Squibb to advance companion diagnostics for precision oncology.
Market Segmentation
By Product
- Kits & Reagents
- Platforms & Instruments
- Services
By Application
- Cancer Therapeutics
- Reproductive Health
- Other Therapeutic Areas
By Circulating Biomarkers
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA)
- Cell-free DNA (cfDNA)
By End-User
- Hospitals
- Diagnostic Laboratories
- Point-of-Care Testing
- Academic Institutes
Conclusion and Future Prospects
The global liquid biopsy market is set for robust growth, fueled by advancements in biomarker technology, increasing cancer prevalence, and shifting preferences toward non-invasive diagnostics. The market will witness increased R&D investments, regulatory approvals, and strategic partnerships, making liquid biopsy a cornerstone of precision medicine and early cancer detection.
For more insights, consult our analysts and get a customized report tailored to your business needs.
